Showing 351-360 of 472 results for "".
- Aesthetics Biomedical Adds Two Executives to its Leadership Teamhttps://modernaesthetics.com/news/aesthetics-biomedical-adds-two-executives-to-its-leadership-team/2473271/Aesthetics Biomedical Inc. (ABM), in its ongoing efforts to meet the increasing demand for its aesthetic products and distribution growth, is continuing to build its executive team. The company recently hired industry experts Derek Harmon as Vice Pres
- FDA Clears Apyx Medical’s Renuvion Handpiece for Improving Lax Skinhttps://modernaesthetics.com/news/fda-clears-apyx-medicals-renuvion-handpiece-for-improving-lax-skin/2473268/The U.S. Food and Drug Administration received 510(k) clearance for the use of Apyx Medical’s Renuvion APR Handpiece for certain skin contraction procedures. Specifically, the Renuvion APR Handpieces are now indicated for use in subcutaneous dermatological and aest
- The Skinny on TikTok Face and Other Social Media Beauty Hackshttps://modernaesthetics.com/news/tiktok-face-and-other-social-media-beauty-hacks/2473267/“TikTok Face” is the media-given name for all sorts of poses (think shielding your face like you're evading the paparazzi) and hacks such as taping to reduce wrinkles or contouring with sunscreen so you look better in your photos and in person. And it’s c
- FDA Nod for Sientra’s Low Plus Profile Projection Breast Implanthttps://modernaesthetics.com/news/fda-nod-for-sientras-low-plus-profile-projection-breast-implant-1/2473263/The U.S. Food and Drug Administration (FDA) approved Sientra’s Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for board-certi
- Trend Alert: New Allergan Aesthetics Report Highlights What’s to Comehttps://modernaesthetics.com/news/trend-alert-new-allergan-aesthetics-report-highlights-whats-to-come/2473254/Consumer interest in medical aesthetics continues to rise, with the number of dermal filler treatments worldwide growing by almost two million between 2017 and 2020, according to Allergan Aesthetics’ 'The Future of Aesthetics' global trends report. In addition, the r
- Cynosure Rolls Out PicoSure Pro Devicehttps://modernaesthetics.com/news/cynosure-rolls-out-picosure-pro-device/2473248/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. The FDA-cleared 755nm picosecond laser on the market, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide
- Cynosure Receives $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://modernaesthetics.com/news/cynosure-recieves-60-million-follow-on-investment-from-clayton-dubilier-rice/2473237/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its cust
- New from Lumenis: triLift Targets Three Elements of Aginghttps://modernaesthetics.com/news/new-form-lumenis-trilift-targets-three-elements-of-aging/2473227/Lumenis Be, Ltd., has launched triLift, a facial stimulation device targeting three aging elements—structure, contour, and texture—by treating the three tissue layers. The device affects the muscl
- Endymed's US Subsidiary Taps Bill Scott as New Presidenthttps://modernaesthetics.com/news/endymeds-us-subsidiary-taps-bill-scott-as-new-president/2473215/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Aquavit's Neurotoxin Submitted to FDAhttps://modernaesthetics.com/news/aquavits-neurotoxin-submitted-to-fda/2473213/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende